{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:34:48Z","timestamp":1780414488446,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T00:00:00Z","timestamp":1583884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Visterra, Inc"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.antiviral.2020.104763","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T20:18:22Z","timestamp":1583525902000},"page":"104763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study"],"prefix":"10.1016","volume":"184","author":[{"given":"Susan E.","family":"Sloan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy J.","family":"Szretter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharathi","family":"Sundaresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M.","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick F.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Skurnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Bedard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Trevejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Oldach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Shriver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104763_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijid.2016.05.013","article-title":"Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies","volume":"49","author":"Balasingam","year":"2016","journal-title":"Int. J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.antiviral.2020.104763_bib2","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.02457-15","article-title":"The hemagglutinin stem-binding monoclonal antibody VIS410 controls influenza virus-induced acute respiratory distress syndrome","volume":"60","author":"Baranovich","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.antiviral.2020.104763_bib3","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-2600(19)30199-7","article-title":"Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial","volume":"7","author":"Beigel","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.antiviral.2020.104763_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2019.04.006","article-title":"Advances in respiratory virus therapeutics - a meeting report from the 6th isirv Antiviral Group conference","volume":"167","author":"Beigel","year":"2019","journal-title":"Antivir. Res."},{"issue":"6","key":"10.1016\/j.antiviral.2020.104763_bib5","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S2213-2600(17)30174-1","article-title":"Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study","volume":"5","author":"Beigel","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"6","key":"10.1016\/j.antiviral.2020.104763_bib6","doi-asserted-by":"crossref","first-page":"R201","DOI":"10.1186\/cc8208","article-title":"Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza","volume":"13","author":"Bermejo-Martin","year":"2009","journal-title":"Crit. Care"},{"issue":"18","key":"10.1016\/j.antiviral.2020.104763_bib7","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.2174\/1381612823666170316123736","article-title":"Cytokines induced during influenza virus infection","volume":"23","author":"Betakova","year":"2017","journal-title":"Curr. Pharmaceut. Des."},{"issue":"1","key":"10.1016\/j.antiviral.2020.104763_bib8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jcv.2013.05.011","article-title":"Cytokine responses in patients with mild or severe influenza A(H1N1)pdm09","volume":"58","author":"Bradley-Stewart","year":"2013","journal-title":"J. Clin. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2020.104763_bib9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1476-5381.1978.tb17276.x","article-title":"Prostaglandin production by macrophages and the effect of anti-inflammatory drugs","volume":"63","author":"Bray","year":"1978","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.antiviral.2020.104763_bib10","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1128\/AAC.43.7.1616","article-title":"Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection","volume":"43","author":"Calfee","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.antiviral.2020.104763_bib11","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S2213-2600(19)30253-X","article-title":"Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial","volume":"7","author":"Davey","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.antiviral.2020.104763_bib12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pharmthera.2009.09.007","article-title":"Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions","volume":"125","author":"Fornai","year":"2010","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104763_bib13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1086\/314938","article-title":"Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment","volume":"180","author":"Fritz","year":"1999","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104763_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/135965350000500305","article-title":"Oral oseltamivir in human experimental influenza B infection","volume":"5","author":"Hayden","year":"2000","journal-title":"Antivir. Ther."},{"issue":"10","key":"10.1016\/j.antiviral.2020.104763_bib15","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.antiviral.2020.104763_bib16","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jama.282.13.1240","article-title":"Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment","volume":"282","author":"Hayden","year":"1999","journal-title":"J. Am. Med. Assoc."},{"issue":"7","key":"10.1016\/j.antiviral.2020.104763_bib17","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1128\/JVI.03099-14","article-title":"Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones","volume":"89","author":"He","year":"2015","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.antiviral.2020.104763_bib18","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1189\/jlb.1108710","article-title":"Immune dysregulation in severe influenza","volume":"85","author":"Heltzer","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.antiviral.2020.104763_bib19","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ebiom.2018.12.051","article-title":"Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: results from a randomized, double-blind, phase-2, placebo-controlled study","volume":"40","author":"Hershberger","year":"2019","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.antiviral.2020.104763_bib20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","volume":"52","author":"Hung","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104763_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41564-019-0609-0","article-title":"Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets","author":"Imai","year":"2019","journal-title":"Nat. Microbiol."},{"issue":"10127","key":"10.1016\/j.antiviral.2020.104763_bib22","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Global Seasonal Influenza-associated Mortality Collaborator, N. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.antiviral.2020.104763_bib23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann. Intern. Med."},{"issue":"38","key":"10.1016\/j.antiviral.2020.104763_bib24","doi-asserted-by":"crossref","first-page":"10172","DOI":"10.1073\/pnas.1707950114","article-title":"Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization","volume":"114","author":"Maamary","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.antiviral.2020.104763_bib25","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.4049\/jimmunol.155.6.3161","article-title":"Monocyte Fc gamma receptor cross-linking induces IL-8 production","volume":"155","author":"Marsh","year":"1995","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.antiviral.2020.104763_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01154-17","article-title":"Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A virus challenge model","volume":"61","author":"McBride","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104763_bib27","series-title":"Options X for the Control of Influenza, Suntec, Singapore","article-title":"A global randomised, double-blind, placebo-controlled study evaluating safety and efficacy of VIS410 in combination with oseltamivir versus oseltamivir alone in hospitalized adults with influenza A requiring oxygen","author":"Oldach","year":"2019"},{"issue":"7","key":"10.1016\/j.antiviral.2020.104763_bib28","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/infdis\/jiu539","article-title":"Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza","volume":"211","author":"Ramos","year":"2015","journal-title":"J. Infect. Dis."},{"issue":"36","key":"10.1016\/j.antiviral.2020.104763_bib29","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1016\/j.vaccine.2008.06.087","article-title":"Co-morbidities associated with influenza-attributed mortality, 1994-2000, Canada","volume":"26","author":"Schanzer","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2020.104763_bib30","series-title":"Design of a Broadly Neutralizing Antibody Targeting Influenza A. Interscience Conference On Antimicrobial Agents And Chemotherapy","author":"Shriver","year":"2012"},{"key":"10.1016\/j.antiviral.2020.104763_bib31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/srep00200","article-title":"Networks link antigenic and receptor-binding sites of influenza hemagglutinin: mechanistic insight into fitter strain propagation","volume":"1","author":"Soundararajan","year":"2011","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.antiviral.2020.104763_bib32","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.12.1900170","article-title":"Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019","volume":"24","author":"Takashita","year":"2019","journal-title":"Euro Surveill."},{"issue":"35","key":"10.1016\/j.antiviral.2020.104763_bib33","doi-asserted-by":"crossref","first-page":"10890","DOI":"10.1073\/pnas.1502374112","article-title":"A broadly neutralizing human monoclonal antibody is effective against H7N9","volume":"112","author":"Tharakaraman","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.antiviral.2020.104763_bib34","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group","volume":"283","author":"Treanor","year":"2000","journal-title":"J. Am. Med. Assoc."},{"issue":"4","key":"10.1016\/j.antiviral.2020.104763_bib35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3851\/IMP3212","article-title":"Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study","volume":"23","author":"Trevejo","year":"2018","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2020.104763_bib36","series-title":"Identification and Characterization of Broadly Neutralizing Antibodies Targeting Influenza IDWeek 2012","author":"Viswanathan","year":"2012"},{"key":"10.1016\/j.antiviral.2020.104763_bib37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.coi.2018.04.026","article-title":"Immunological responses to influenza vaccination: lessons for improving vaccine efficacy","volume":"53","author":"Wang","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.antiviral.2020.104763_bib38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ebiom.2016.02.021","article-title":"Safety and upper respiratory pharmacokinetics of the hemagglutinin stalk-binding antibody VIS410 support treatment and prophylaxis based on population modeling of seasonal influenza A outbreaks","volume":"5","author":"Wollacott","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.antiviral.2020.104763_bib39","series-title":"Global Influenza Strategy 2019-2030","author":"WorldHealthOrganization","year":"2019"},{"issue":"1","key":"10.1016\/j.antiviral.2020.104763_bib40","doi-asserted-by":"crossref","first-page":"17464","DOI":"10.1038\/s41598-019-53945-1","article-title":"Molecular dynamics simulation reveals the mechanism by which the influenza cap-dependent endonuclease acquires resistance against baloxavir marboxil","volume":"9","author":"Yoshino","year":"2019","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.antiviral.2020.104763_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028680","article-title":"Intensive cytokine induction in pandemic H1N1 influenza virus infection accompanied by robust production of IL-10 and IL-6","volume":"6","author":"Yu","year":"2011","journal-title":"PloS One"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219307260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219307260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:33:13Z","timestamp":1759062793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219307260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":41,"alternative-id":["S0166354219307260"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104763","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Visterra, Inc. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104763"}}